Following 'Wooden Sister': Aggressively building positions in the AI chip rising star CBRS, taking profits at highs on Taiwan Semiconductor and AMD, continuing to divest traditional medical diagnostics stocks

On Thursday (May 14), the three major U.S. stock indexes closed higher across the board, with the Nasdaq and S&P 500 both hitting new highs, while the Dow Jones Industrial Average breached the 50,000 mark for the first time in three months. Technology stocks led the market surge as investors continued to monitor developments regarding Trump's visit to China and the situation in the Middle East.

Under these market conditions, 'Wood姐' (Cathie Wood) demonstrated decisive portfolio adjustments inMay 14, showing an intergenerational 'hardware rotation' and a significant reshuffle in biotechnology:On the buying side, she heavily invested in CBRS, a disruptor in the AI computing infrastructure sector; on the selling side, she took profits at high levels from global semiconductor manufacturing leader Taiwan Semiconductor and AI chip giant AMD, continuing her liquidation of traditional genetic diagnostic sectors.

Buying focus: An 'intergenerational rotation' within the AI computing track, placing concentrated bets on disruptive chip players

– $Cerebras Systems (CBRS.US)$—Aggressively purchasing 105,600 shares, strategically betting on the WSE chip dark horse, Cerebras was yesterday’s highly anticipated AI chip unicorn, surging 68% on its first day of listing. Known for its groundbreaking 'Wafer-Scale Engine (WSE)' technology, it addresses data transmission bottlenecks during the training of large AI models via a single ultra-large chip.

In a previous article {Cerebras is about to go public! Can the only wafer-scale AI chip shake NVIDIA's dominant position?》we also discussed the interpretation of the company's IPO-related opportunities; interested fellow investors can check it out.

Combining the day's sell-off reductions in Taiwan Semiconductor and AMD, this is a classic case of "sector rotation." ARK is shifting capital towards emerging computing infrastructure with explosive cash-out potential, which could disrupt existing paradigms in specific AI training scenarios.

Sell-side direction: Semiconductor giants taking profits at highs, fully liquidating 'sunk cost' legacy healthcare

– Taiwan Semiconductor (TSM), Advanced Micro Devices (AMD) & Teradyne (TER) — Profit-taking on chip giants at elevated levels

Significant reduction in the world's leading chip foundry $Taiwan Semiconductor (TSM.US)$41,500 shares of the global chip leader, AI chip giant $Advanced Micro Devices (AMD.US)$11,500 shares, and semiconductor testing equipment provider $Teradyne (TER.US)$22,600 shares.Recently, driven by expectations of insufficient AI production capacity, the semiconductor sector's valuation has repeatedly hit new highs. From an institutional investor’s perspective, these positive expectations are already highly reflected in current stock prices. ARK chose to collectively sell off these three core companies in the semiconductor supply chain at this stage—a typical example of "profit-taking at highs," securing the substantial gains earned during the AI hardware boom and reallocating liquidity for building positions in rising stars like CBRS.

– ADPT & CDNA — Ruthless liquidation of traditional genetic diagnostics stocks

Reduction in holdings of immune sequencing company $Adaptive Biotechnologies (ADPT.US)$35,100 shares, as well as organ transplant diagnostic companies $CareDx (CDNA.US)$13,500 shares.This continues ARK's biotech portfolio adjustment logic since May. In the context of the strong rise of precision medicine leaders like Natera, which have powerful clinical data moats, ADPT and CDNA are facing challenges such as eroding market share and weak growth. ARK is removing traditional diagnostic assets that lack AI algorithm empowerment and pricing power.

– TWST — Continued reduction post-earnings, avoiding cash burn risks in a high-interest environment

Continued selling $Twist Bioscience (TWST.US)$ 11,600 shares.This marks ARK's consecutive days of selling this synthetic biology company. In the current macro environment of high capital costs, market tolerance for companies mired in continuous losses is extremely low. Withdrawing funds from TWST, whose commercialization process has been slow, is a routine move to optimize portfolio capital efficiency.

Futubull [Opportunities page] Now featuring the ability to track portfolios of renowned investors! Choose from multiple celebrity holdings, follow the investment strategies of top players with one click, accurately target high-quality stocks, and invest with greater confidence!

233K Views